Obeticholic acid: towards first approval for NASH
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The response rate and efficacies of FXR agonists in clinical trials were not optimum.
“Although various FXR agonists have shown anti-fibrotic effects in diverse preclinical animal models, the response rate and efficacies in clinical trials were not optimum.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [20]
The response rate of OCA treatment to NASH-induced liver fibrosis is only 23%.
“However, the response rate of OCA treatment to NASH-induced liver fibrosis is only 23%.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [20]
In phase III clinical trials, OCA has reached one of the primary endpoints in NASH-associated fibrosis.
“In phase III clinical trials, OCA, a potent FXR agonist, has reached one of the primary endpoints in NASH-associated fibrosis.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [20]
Cites
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · see citing works
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836 · see citing works
Byrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,082 · see citing works
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890 · see citing works
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · see citing works
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277 · see citing works
Younossi, Z. M., Stepanova, M., Ong, J. P., Jacobson, I. M., Bugianesi, E., Duseja, A. K., Eguchi, Y., Wong, V. W., Negro, F., Yilmaz, Y. N., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.05.057 · Cited by 807 · see citing works
Vilar-Gomez, E., Calzadilla-Bertot, L., Wai-Sun Wong, V., Castellanos, M., Aller-de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quiñones Sanz, M., Conde-Martin, A. F., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.034 · Cited by 806 · see citing works
Self-citationFXR: a metabolic regulator and cell protector
Wang, Y.-D., Chen, W.-D., Moore, D. D., & Huang, W. (2008) · Cell Research · doi:10.1038/cr.2008.289 · Cited by 389 · see citing works
Siddiqui, M. S., Harrison, S. A., Abdelmalek, M. F., Anstee, Q. M., Bédossa, P., Castéra, L., Dimick‐Santos, L., Friedman, S. L., Greene, K., Kleiner, D. E., et al. (2017) · Hepatology · doi:10.1002/hep.29607 · Cited by 165 · see citing works
Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers
Pencek, R., Marmon, T., Roth, J. D., Liberman, A., Hooshmand-Rad, R., & Young, M. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12681 · Cited by 67 · see citing works
Labenz, C., Prochaska, J. H., Huber, Y., Nagel, M., Straub, B. K., Wild, P. S., Galle, P. R., & Schattenberg, J. M. (2019) · Hepatology Communications · doi:10.1002/hep4.1428 · Cited by 35 · see citing works
Drug development: Sprint finish
Drew, L. (2017) · Nature · doi:10.1038/d41586-017-06926-1 · Cited by 24 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375 · see citing works
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
Zhou, J., Cui, S., He, Q., Guo, Y., Pan, X., Zhang, P., Huang, N., Ge, C., Wang, G., Gonzalez, F. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14138-6 · Cited by 154 · see citing works
Macrophages in metabolic associated fatty liver disease
Alharthi, J., Latchoumanin, O., George, J., & Eslam, M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i16.1861 · Cited by 65 · see citing works
Self-citation
- Authors
- Eslam, M., Alvani, R., & Shiha, G.
- Affiliations
- The University of Sydney (AU)
- University of Indonesia (ID)
- Mansoura University (EG)
- Corresponding author
- Eslam, Mohammed
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 394
- Issue
- 10215
- Pages
- 2131-2133
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2993239715
- Cited by
- 43
- References
- 13
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 5 · 2020: 13
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- obeticholic acid, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, fibrosis, drug approval, histological improvement, hepatocellular carcinoma risk, liver transplantation
- MeSH terms
- Chenodeoxycholic Acid, Humans, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
